Epigamia co-founder Rohan Mirchandani passes away at 42 due to sudden cardiac arrest

Rohan Mirchandani, co-founder of Epigamia, India’s leading Greek yogurt brand, passed away at the age of 42 due to cardiac arrest. The news was confirmed by Epigamia’s parent company, Drums Food International.

“All of us at the Epigamia family will deeply mourn this loss. Rohan was our mentor, friend, and leader. We remain steadfast in our determination to carry forward his dream with strength and vigor,” the company said in an official statement.

Mirchandani, an alumnus of NYU Stern and The Wharton School, co-founded Drums Food International in 2013. Initially launching with Hoki Poki ice cream, the company transitioned under his leadership to Epigamia, which now boasts a presence in over 20,000 retail outlets across 30 cities.

Also Read ICICI Prudential Life tops with claim settlement ratio of 99.04% in Q2 FY2025 – Check where other insurers stand Who was Siyaram Baba, MP seer who devoted his life to Narmada River? SM Krishna passes away: All about veteran statesman who put Bengaluru on global map Who is Abu Mohammed al-Golani, rebel leader behind fall of Damascus and Assad’s government in Syria?

Also ReadCCI strikes a fine balance: regulator and business facilitator

To ensure continuity, the company announced that daily operations would be managed by senior leaders Ankur Goel, COO and Founding Member, and Uday Thakker, Co-founder and Director, with support from the Board of Directors, including Rohan’s family, Raj Mirchandani, and key investors Verlinvest and DSG Consumer Partners.

Mirchandani’s vision extended beyond India, with plans to expand into the Middle East by 2025-26. “Rohan was our mentor, friend, and leader. We remain committed to carrying forward his vision,” Goel and Thakker affirmed in their statement.

 » Read More

Related Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain